Profile
| Role | Director |
|---|---|
| Notability | 20/100 |
Board memberships
- Xeris Biopharma Holdings, Inc.
Updated Jul 16, 2026
PERSKY MARLA has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $211K.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | XERS | Xeris Biopharma Holdings, Inc. | A — Grant or award | 24.2K | $0.00 | |
| 2026-06-05 | XERS | Xeris Biopharma Holdings, Inc. | S — Open-market sale | 15.5K | $5.90 | $91K |
| 2025-09-11 | XERS | Xeris Biopharma Holdings, Inc. | S — Open-market sale | 15.5K | $7.72 | $120K |
| 2025-06-04 | XERS | Xeris Biopharma Holdings, Inc. | A — Grant or award | 50.0K | $0.00 |
PERSKY MARLA is a corporate insider — currently tracked as Director of Xeris Biopharma Holdings, Inc. (XERS). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($211K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live PERSKY MARLA profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.